ASIA-PACIFIC CELL THERAPY MARKET FORECAST 2022-2030

The Asia-Pacific cell therapy market growth is anticipated to progress at a CAGR of 15.16% during the forecast period, 2022-2030, and is expected to reach a revenue of $1074.70 million by 2030.

The cell therapy market growth in Asia-Pacific is attributed to the progress made in stem cell treatment in several Asian countries. Also, Asia is at the forefront of stem cell research. In addition, many stem cell consortiums exist in Asian nations that provide concentrated and coordinated R&D efforts.

Besides, there is growing migration of patients from western countries, accredited to the flexible legal framework. Moreover, global companies are entering the industry, given the region’s large population base and unexplored potential. However, Asia-Pacific cell therapy market growth is hampered by high costs.

To know more about this report, request a free sample copy

The Asia-Pacific cell therapy market growth analysis includes the assessment of Singapore, Thailand, Japan, China, India, Australia & New Zealand, Singapore, and Rest of Asia-Pacific.

According to Nature, a leading multidisciplinary science journal, CAR T-cell therapy clinical trials make up over 50% of all cell and gene therapy studies in China. Also, around 200 CAR-T studies are being conducted, encompassing various indications and targets from hematology-oncology to solid tumors. In addition, China has established itself as a global leader in cell and gene therapy (CGT) development, ranking second globally, with more than 1000 clinical trials either in progress or completed. This is majorly attributed to the country’s robust policy backing. Besides, China has a flourishing cell and gene therapy biotech industry, headed by over 45 local companies and four partnerships with international partners with CGT pipelines for investigational new drugs (INDs).

Furthermore, there have been significant developments in CGT as part of the new wave of advanced therapy medicinal products (ATMP) that offers patients with new hope. Additionally, the government published a number of progressive policies between 2018 and 2019 under the direction of the National Health Commission (NHC) and the National Medical Products Administration (NMPA) to strengthen regulations in the CGT industry. Such developments have facilitated a transparent framework that healthcare organizations and R&D-stage companies use to get regulatory licenses for CGT therapies. These factors drive the cell therapy market growth in China.

The Asia-Pacific cell therapy market segmentation includes the analysis of therapeutic application, end-user, therapy type, and cell type. The end-user segment includes academic & research institutes and hospitals & clinics.

With regard to academic & research institutes, the ongoing research for cancer and the rising investments in R&D through public and private partnerships are projected to boost the segment’s growth. For instance, panCella, an early-stage biotechnology company, received approximately $305078.5 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for the R&D of its technology platforms used for cell therapy. Such investments are projected to raise the demand for instruments to conduct research for cell therapies.

For instance, the Oxford Stem Cell Institute (OSCI), a division of Oxford University, encompasses 45 core and associated laboratories spread out over Oxford. They aim to create more potent stem cell and anti-cancer therapies backed by a diverse group of experts. In addition, more than 1000 scientists work at the Harvard Stem Cell Institute (HSCI), which boasts the world’s concentration of biomedical researchers. Their objective is to accelerate the delivery of stem cell-based therapies to patients.

Some of the leading companies in the Asia-Pacific cell therapy market include JCR Pharmaceuticals Co Ltd, Mesoblast Limited, Kolon TissueGene Inc, MEDIPOST Co Ltd, etc.

JCR Pharmaceuticals specializes in the development of pharmaceutical products and is engaged in the research & discovery of therapeutic drugs for lysosomal storage diseases. It is headquartered in Ashiya, Japan.

One of its key products, TEMCELL®HS Inj, is a Mesenchymal Stem Cell (MSC)-based allogeneic regenerative medical product designed for treating acute Graft-Versus-Host Disease (acute GvHD).

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.